Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donepezil - Eisai

Drug Profile

Donepezil - Eisai

Alternative Names: Aricept; Aricept D; Aricept Dry Syrup; Aricept Evess; Aricept ODT; Aricept SR; Donepezil hydrochloride; Donepezil SR; E 2020; E 2022; Eranz

Latest Information Update: 03 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; Pfizer; Teikoku Pharma USA; Teikoku Seiyaku
  • Class Antidementias; Indans; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Lewy body disease; Vascular dementia
  • Phase III Down syndrome
  • No development reported Attention deficit and disruptive behaviour disorders; Migraine
  • Discontinued Aphasia; Attention-deficit hyperactivity disorder; Dementia; Mild cognitive impairment

Most Recent Events

  • 31 Oct 2022 Eisai received Category 2* status for the treatment of dementia with Lewy bodies (DLB) in Japan
  • 30 Dec 2021 Teikoku Seiyaku completes a phase-III clinical trials in Alzheimer's disease in Japan, prior to December 2021 (PO) (JapicCTI-194683)
  • 09 Aug 2021 Pfizer initiates the phase III trial for Alzheimer's disease in Czech Republic, Finland, Germany, Greece and Spain (PO)(EudraCT2004-004918-17).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top